Eloquence

Cincom Systems partners with Sapiens to deliver better customer experiences through automated correspondence processing

Retrieved on: 
Thursday, May 25, 2023

The partnership will make effective customer communications to insurers easier for Sapiens customers via the Cincom Eloquence® platform.

Key Points: 
  • The partnership will make effective customer communications to insurers easier for Sapiens customers via the Cincom Eloquence® platform.
  • Eloquence will play a key role in helping enhance customer experience within the Sapiens CoreSuite offering with more timely, relevant and personalized communications across the entire policyholder lifecycle.
  • "Together, Cincom and Sapiens will help simplify the correspondence process for users of Sapiens CoreSuite, leading to better customer experience, improved compliance, and brand consistency."
  • "The Cincom and Sapiens partnership will provide simplified and streamlined correspondence processes, which can help businesses operate more efficiently, reduce costs, improve accuracy, and provide a better customer experience."

Xerox’s PARC Announces Novity, a New Venture to Address Unplanned Downtime in Industrial Manufacturing

Retrieved on: 
Wednesday, March 9, 2022

PARC , a Xerox company, announced today the launch of Novity , a new venture to commercialize predictive maintenance (PdM) technology that reduces unplanned downtime in industrial manufacturing operations.

Key Points: 
  • PARC , a Xerox company, announced today the launch of Novity , a new venture to commercialize predictive maintenance (PdM) technology that reduces unplanned downtime in industrial manufacturing operations.
  • This allows Novity to predict equipment failures with 90 percent or better accuracy and lead times of months, not weeks or days.
  • Our goal with this solution is to solve these problems, ultimately enabling zero unplanned downtime.
  • Within the first month, the system picked up a potential issue with a mill, allowing us to take preventative action, avoiding costly unplanned downtime.

Xerox Joint Venture Eloque Announces Plans to Triple Bridge Installs in First Half of 2022

Retrieved on: 
Wednesday, February 2, 2022

The recently enacted Bipartisan Infrastructure Act in the United States includes $27 billion for bridge repair, which will help U.S. states significantly reduce the repairs backlog.

Key Points: 
  • The recently enacted Bipartisan Infrastructure Act in the United States includes $27 billion for bridge repair, which will help U.S. states significantly reduce the repairs backlog.
  • However, the total estimated cost to rehabilitate all bridges in the United States classified as structurally deficient is $125 billion.
  • About Xerox Holdings Corporation (NASDAQ: XRX)
    For more than 100 years, Xerox has continually redefined the workplace experience.
  • Xerox and Eloque are trademarks of Xerox in the United States and/or other countries.

New Study Presents Impressive Results of Nexstim SmartFocus® nTMS Language Mapping

Retrieved on: 
Wednesday, January 13, 2021

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that a new study published in Cancers in January presents impressive results of nTMS language mapping in a large amount of patients.

Key Points: 
  • Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that a new study published in Cancers in January presents impressive results of nTMS language mapping in a large amount of patients.
  • The study Non-Invasive Mapping for Effective Preoperative Guidance to Approach Highly Language-Eloquent GliomasA Large Scale Comparative Cohort Study Using a New Classification for Language Eloquence , using Nexstims NBS System with SmartFocus nTMS, was published by a neurosurgical team at Technical University of Munich (TUM) in Germany.
  • Nexstim SmartFocus nTMS pre-operative language mapping was performed on all these patients.
  • This distinguished study shows how Nexstims SmartFocus nTMS mapping can help to get very high gross total resection rates in language eloquent brain tumour surgeries without jeopardizing patients language function.